退市高危股名单曝光。 *ST万方(000638)1月13日盘后发布公告，经公司财务部门初步测算结果，预计公司2025年度营业收入低 于3亿元，且利润总额、净利润或者扣除非经常性损益后的净利润孰低者为负值。根据《深圳证券交易 所股票上市规则》的相关规定，2025年度经审计营业收入低于3亿元且利润总额、净利润或者扣除非经 常性损益后的净利润孰低者为负值的，公司股票将因触及财务类退市情形被终止上市。 在此消息影响下，1月14日上午该股一字跌停。截至上午收盘，*ST万方报4.57元/股，下跌4.99%，封单 超66万手。 | 营加 | 多股 | 统计 | 圖幾 | F10 | 标记 +自选 返回 | | *ST万方 000638 | | | 农林牧渔 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | ◇ □ | | 4.57 -0.24 -4.99% | | | 0.78% | | | | | | | | | 2017 | 4.61 | 8 | | | | | | | | | 7.50 | 壶川 | 4. ...

1月14日，经中国证监会批准，沪深北交易所发布通知调整融资保证金比例，将投资者融资买入证券时的融资保证金最低比例从80%提高至100%。 2023年8月，沪深北交易所将融资保证金比例从100%降低至80%，融资规模和交易额稳步上升。近期，融资交易明显活跃，市场流动性相对充裕，根 据法定的逆周期调节安排，适度提高融资保证金比例回归100%，有助于适当降低杠杆水平，切实保护投资者合法权益，促进市场长期稳定健康发 展。 需要说明的是，此次调整仅限于新开融资合约，调整实施前已存续的融资合约及其展期仍按照调整前的相关规定执行。 校对：吕久彪 ...

据证券时报网报道，中信建投研报表示，负债端看好分红险持续承接居民稳健投资需求并驱动新单实现 快速增长，资产端权益市场向好有望带来业绩弹性，建议重视保险板块配置机会。中信建投认为当前储 蓄险销售和分红险转型正迎来多种利好因素的共振，一是中长期存单供给收缩和利率波动环境下，储蓄 险产品相对优势更加显著。二是分红险在需求端的市场接受度和供给端的队伍销售能力预计有所提升; 三是"报行合一"带动银保渠道价值率改善后头部险企积极加大银保渠道布局。第四，储蓄险产品作为后 资管新规时代少数可提供长期确定收益的金融产品，在净值化转型、非标转标驱动居民财富配置重构的 过程中有望持续承接居民庞大的稳健投资需求。 ...

Core Viewpoint - The A-share and Hong Kong stock markets have seen significant increases in the GEO (Generative Engine Optimization) concept, with notable stock performances and a surge in related announcements and risk warnings from companies [2][4]. Group 1: Market Performance - The A-share GEO concept index rose over 8% in the morning session, with stocks like Liujin Technology increasing by more than 26%, and several others hitting the daily limit of 20% [2]. - In the Hong Kong market, the GEO concept index also saw a rise of over 4%, with stocks such as Zhiyuan increasing by over 19% and Weimeng Group by over 9% [4]. - Since 2026, several stocks in the GEO index have experienced cumulative increases exceeding 50%, with some doubling in value [4]. Group 2: Company Responses and Clarifications - Companies like Huichen Co. have actively responded to inquiries about GEO, highlighting their solutions that cater to AI-driven brand marketing needs, leveraging their extensive experience in data and algorithm models [6]. - Measurement Co. clarified that while GEO is a new optimization strategy for generative AI, they are not currently involved in related business [7]. - Zhejiang Wenhu has issued a risk warning, stating that their GEO business has not yet developed a mature profit model and lacks revenue [8]. - Other companies, including Inertia Media and People's Daily, have also confirmed that they do not engage in GEO-related activities and have not identified any significant media reports affecting their stock prices [8][9].

据公开资料，2025年中国磷酸铁锂产量392.02万吨。根据产量划分，湖南裕能维持头部位置，年产量突破100万吨；富临精工增量较大，进入第二梯队， 与万润新能、德方纳米在30万吨级水平竞争；友山科技、国轩高科、龙蟠科技维持在20万吨级水平；泰丰先行、四川协鑫、安达科技稳定增量，定格10万 吨级。据此，不难理解容百科技在磷酸铁锂行业中的排序。 据了解，容百科技主要从事正极材料，产品覆盖三元材料、磷酸锰铁锂、钠电正极，其中以三元材料在业界较为知名。2025年上半年，公司三元材料销量 5万吨。 磷酸铁锂与三元材料为锂电池两大主流技术分类，但近年来，磷酸铁锂的市场用量大增，对三元材料形成碾压式的冲击。根据公开资料，目前，磷酸铁锂 电池和三元电池占比，约为8:2。 在此背景之下，从事三元材料的容百科技开始变道，2025年，公司宣布正式进入磷酸铁锂领域。根据此前披露，容百科技采用低成本、高性能的全新生产 工艺切入该赛道。公司已经启动海外市场开拓、产线设计等工作，有望在波兰建成首条欧洲磷酸铁锂产线。 停牌！1月14日，容百科技（688005）在披露千亿大单后，遭到交易所连夜问询，公司股票也在今天全天停牌，理由是重要事项未公 ...

证券时报•数据宝统计显示，1月13日有39家香港上市公司进行了股份回购，合计回购1751.51万股，回 购金额8.96亿港元。 腾讯控股回购数量101.20万股，回购金额6.36亿港元，回购最高价为638.000港元，最低价为623.000港 元，年内累计回购金额50.86亿港元；小米集团-W回购数量400.00万股，回购金额1.52亿港元，回购最 高价为38.040港元，最低价为37.940港元，年内累计回购金额9.42亿港元；舜宇光学科技回购数量64.00 万股，回购金额4178.78万港元，回购最高价为65.800港元，最低价为64.550港元，年内累计回购金额 2.29亿港元。 以金额进行统计，1月13日回购金额最多的是腾讯控股，回购金额为6.36亿港元；其次是小米集团-W， 回购金额为1.52亿港元；回购金额居前的还有舜宇光学科技、巨子生物等。回购数量上看，1月13日回 购股数最多的是小米集团-W，当日回购量为400.00万股；其次是捷利交易宝、碧桂园服务等，回购数 量分别为180.80万股、139.40万股。（数据宝） 1月13日港股公司回购一览 （万股） 回购金额 （万港元） 回购最高价 （港元 ...

Core Viewpoint - Shandong Pharmaceutical Glass (山东药玻) plans to raise approximately 3.235 billion yuan by issuing shares at a price of 16.25 yuan per share, with the funds aimed at enhancing liquidity and supporting its transformation into a technology-driven international enterprise [1][2] Group 1: Company Overview - Shandong Pharmaceutical Glass, established in 1970, is a leading enterprise in the pharmaceutical glass industry and was listed on the Shanghai Stock Exchange in June 2002 [2] - The company specializes in the production of pharmaceutical glass products, including molded glass bottles, glass tubes, ampoules, and infusion bottles, with over 200 product varieties [2] - The market share of its molded glass bottles exceeds 85%, indicating a strong position in the domestic market [2] Group 2: Strategic Changes - Following the share issuance, China National Pharmaceutical Group (国药集团) will become the controlling shareholder, with the actual controller changing to the State-owned Assets Supervision and Administration Commission of the State Council [1] - The transition to being controlled by a major state-owned enterprise is expected to enhance the company's ability to align with national strategies and improve its capabilities in pharmaceutical research and development [1][2] Group 3: Funding Utilization - The raised funds will be used to enhance research and innovation capabilities, invest in new technologies and products, and strengthen core competitive products in various pharmaceutical packaging materials [2] - The company aims to accelerate the integration of its product offerings, creating a comprehensive system that includes bottles, stoppers, caps, and drug delivery systems [2]

Core Viewpoint - A-share companies are expected to report significant profit growth for 2025, with several companies projecting year-on-year increases exceeding 100% [1][2]. Group 1: Company Performance Forecasts - Baiwei Storage anticipates a net profit of 850 million to 1 billion yuan for 2025, representing a year-on-year growth of 427.19% to 520.22% [2][4]. - Chenguang Biological expects a net profit of 350 million to 405 million yuan for 2025, with a growth rate of 272.14% to 330.62% [2][9]. - TCL Technology forecasts a net profit of 4.21 billion to 4.55 billion yuan for 2025, indicating a growth of 169% to 191% [2][9]. - Dazhu CNC predicts a net profit of 785 million to 885 million yuan for 2025, with a growth of 160.64% to 193.84% [2][10]. - WoHua Pharmaceutical expects a net profit of 80 million to 115 million yuan for 2025, with a growth rate of 119.76% to 215.90% [2][11]. - Haopeng Technology anticipates a net profit of 195 million to 220 million yuan for 2025, with a growth of 113.69% to 141.09% [2][11]. - Changlan Technology forecasts a net profit of 130 million to 160 million yuan for 2025, with a growth of 74.07% to 114.24% [2][11]. Group 2: Factors Driving Growth - Baiwei Storage attributes its significant profit growth to a recovery in storage prices and the delivery of key projects, leading to improved sales revenue and gross margins [4][5]. - Chenguang Biological's growth is driven by increased revenue and gross profit from its plant extraction business, particularly in chili red and other products [9]. - TCL Technology's growth is supported by its focus on semiconductor displays, new energy photovoltaics, and semiconductor materials, achieving high-quality growth with substantial revenue and cash flow [9]. - Dazhu CNC's growth is fueled by rising demand for high-layer boards and PCB manufacturing driven by AI infrastructure investments [10]. Group 3: Market Trends and Investment Opportunities - The report from CICC highlights that the upcoming earnings disclosures may reveal sectors and companies with improved or exceeding expectations, which could attract investor attention [2]. - Key areas of focus include sectors benefiting from AI technology, such as TMT, innovative pharmaceuticals, energy storage, and solid-state batteries, which are entering a growth cycle [11][12]. - The report suggests that companies with overseas expansion strategies, particularly in home appliances, engineering machinery, and non-ferrous metals, may present reliable growth opportunities [11][12].

当地时间1月13日，美国股市三大股指全线收跌，其中道琼斯工业指数跌0.8%，报49191.99点。标准普尔500指数跌0.19%，报6963.74点，纳斯达克指数跌 0.1%，报23709.87点。 宏观消息面上，据央视新闻客户端报道，美国财政部表示，受支出创纪录及福利支付时间调整影响，美国政府2025年12月录得1450亿美元财政赤字，同比 增加67%，创下该月份历史新高。 美股市场金融股整体大跌，其中摩根大通领跌市场，收盘大跌超4%。其他金融股中，摩根士丹利跌逾2%，高盛、花旗、美国银行、富国银行均跌逾1%。 和金融有关的公司股票中，VISA跌逾4%，该股盘中一度跌超5%。 当地时间1月13日，美国股市三大股指全线收跌，其中金融板块整体大跌，拖累美股市场整体表现。中概股亦普遍下跌，纳斯达克中国金龙指数跌 1.86%。 贵金属市场中，国际银价再创历史新高。 美股三大股指收跌 金融股大跌 能源股集体上涨，埃克森美孚涨近2%，斯伦贝谢、西方石油均涨逾1%，雪佛龙、康菲石油均涨近1%。 抗疫概念股多数上涨，Moderna涨超17%，诺瓦瓦克斯医药涨近12%，BioNTech涨近5%，阿斯利康涨近1%，吉利德科学跌 ...

Core Viewpoint - Fenglong Co., Ltd. (002931) announced a stock trading suspension for verification due to a significant price increase of 213.97% over 12 consecutive trading days, which deviated from the company's fundamentals [1][3] Group 1: Stock Performance and Trading Suspension - Fenglong's stock experienced a remarkable surge, achieving 13 consecutive daily price limits from December 17, 2025, to January 13, 2026, with a total increase of 245.39% [6] - The stock price reached a limit of 61.79 yuan per share, resulting in a total market capitalization of 13.5 billion yuan as of January 13 [6] - The company will suspend trading starting January 14, 2026, for no more than three trading days to conduct a verification of the stock price fluctuations [3] Group 2: Acquisition and Business Strategy - UBTECH Robotics announced the acquisition of 43% of Fenglong's shares (93.9575 million shares) for a total consideration of 1.665 billion yuan, changing the controlling shareholder from Chengfeng Investment to UBTECH [3][4] - The acquisition aims to create business synergies, enhancing UBTECH's product competitiveness and optimizing cost structures by integrating its humanoid robot technology with Fenglong's manufacturing capabilities [4] - UBTECH plans to increase its industrial humanoid robot production capacity to 10,000 units by 2026, with Fenglong's manufacturing capabilities providing essential support [4]